In his weekly clinical update, Dr. Griffin deep dives into infections of dairy cattle with high pathogenic influenza H5N1, how long virus has been circulating and if known anti-influenza antivirals can reduce secondary attack rates, before reviewing the recent statistics on SARS-CoV-2 infection, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster takes associates with long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, if administration of oral antiviral therapies can prevent the onset of post-acute sequelae following SARS-CoV-2 infection, continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, compares and contrasts the cognitive profile in multiple sclerosis and post-COVID, exercise intolerance following SARS-CoV-2 infection and the epidemiology of the pandemic in a Kenyan refugee camp. For more information about this body of work, listen to TWiV 1088.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Technical reports on high path avian influenza (CDC)
• High path cow influenza H5N1 clade 2.3.4.4b (Emerging Infectious Diseases)
• Cow flu flying around for 4 months (CNN)
• Interstate commerce: high path avian influenza in dairy cattle (bioRxiv)
• Oseltamivir and baloxavir marboxil treatment for influenza in household index cases (Influenza and other respiratory viruses)
• COVID-19 national trend (CDC)
• COVID-19 deaths (CDC)
• Spring vaccine advice (CIDRAP)
• Older adult spring booster available (CDC)
• Advisory committee for immunization practices slides (CDC)
• Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)
• EUA for pemgarda (FDA)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (IDSociety)
• Overuse ofantibiotics for COVID-19: a viral disease (European Soc Clin Micro Inf Dis)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio)
• Updated respiratory virus guidances (CDC)
• What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Antiviral effect of metformin on SARS-CoV-2 viral load (CID)
• Nirmatrelvir-ritonavir to prevent post-acute sequelae and mortality in SARS-CoV-2 hospitalized patients (Lancet Infectious Diseases)
• Oral antivirals for acute and post-acute sequelae from SARS-CoV-2 infection (Lancet Infectious Diseases)
• Nirmatrelvir-ritonavir for prevention of COVID-19 related hospitalization (American Journal of Therapeutics)
• Nirmatrelvir-ritonavir effectiveness (American Therapeutics)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Long COVID evidence based review TWiV shout out (TWiV 1088)
• Cognitive profile in multiple sclerosis and post-COVID (Scientific reports)
• Exercise intolerance in long COVID (American Journal of Medicine)
• Epidemiology of SARS-CoV-2 in the Kakuma refugee camp, Kenya (Emergining Infectious Diseases)
• Rohingya refugees (USA for UNHCR)
• Contribute to our Floating Doctors fundraiser
• Letters read on TWiV 1112
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]